lenalidomide transdermal (STAR-LLD TDS) / Starton Therap - LARVOL DELTA

Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application 17/518,930 “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” Including Transdermal Administration (GlobeNewswire) - "Starton Therapeutics Inc...announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/518,930, covering STAR-LLD, the Company’s continuous delivery lenalidomide program....Once granted, the patent expected to issue from the pending application will have a term extending to 2040, excluding any patent term adjustments or patent term extensions that may provide additional protection."

Patent • Chronic Lymphocytic Leukemia • Multiple Myeloma

Starton Therapeutics Completes One Third of STAR-LLD Study Enrollment (GlobeNewswire) - "Two patients have been dosed and a third is in screening. The first patient has completed cycle 1 successfully where he obtained a measurable response with a decrease in M-protein from 1.7 to 0.9 gm/dL (47% reduction) with no adverse events noted and has begun cycle 2. Second patient similarly completed the first week without untoward effects."

Enrollment status • Hematological Malignancies • Multiple Myeloma • Oncology